Huntexil (pridopidine) / Prilenia  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Huntexil (pridopidine) / Prilenia
HART, NCT00724048: A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

Completed
2
227
Canada, US
ACR16, pridopidine, Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Huntington Disease
07/10
07/10
NCT02006472 / 2013-001888-23: A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Completed
2
408
Europe, Canada, US, RoW
Pridopidine, TV7820, Placebo
Prilenia, European Huntington's Disease Network, Huntington Study Group
Huntington's Disease
12/15
07/16
OPEN-HART, NCT01306929: Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease

Completed
2
134
NA
pridopidine
Prilenia
Huntington Disease
01/18
01/18
Open PRIDE-HD, NCT02494778 / 2015-000904-24: A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

Terminated
2
248
Europe, Canada, US, RoW
Pridopidine, TV7820
Prilenia
Huntington's Disease
01/18
01/18
NCT03922711: A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

Terminated
2
23
US
Pridopidine, Placebo
Prilenia
Parkinson Disease
07/20
07/20

Download Options